Acer Therapeutics Inc. (ACER): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACER Stock Summary
- Acer Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.39% of US listed stocks.
- For ACER, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- As for revenue growth, note that ACER's revenue has grown -68.48% over the past 12 months; that beats the revenue growth of only 1.98% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acer Therapeutics Inc are FUV, AFIB, CODX, KN, and CLIR.
- ACER's SEC filings can be seen here. And to visit Acer Therapeutics Inc's official web site, go to www.acertx.com.
ACER Valuation Summary
- ACER's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ACER.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACER | 2021-08-31 | 9.4 | 4.8 | -2.2 | -0.9 |
| ACER | 2021-08-30 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-27 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-26 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-25 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-24 | 9.2 | 4.7 | -2.2 | -0.8 |
ACER Growth Metrics
- Its 5 year revenue growth rate is now at -100%.
- Its 5 year net cashflow from operations growth rate is now at -93.43%.
- The 4 year cash and equivalents growth rate now stands at -29.61%.
The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 1.26 | -0.134909 | -15.37399 |
| 2021-09-30 | 0.9 | -2.594543 | -17.19103 |
| 2021-06-30 | 3.998133 | 0.915877 | -16.90639 |
| 2021-03-31 | 3.998133 | -8.952031 | -19.44992 |
| 2020-12-31 | 0 | -17.02742 | -22.88545 |
| 2020-09-30 | 0 | -17.13891 | -21.80405 |
ACER Price Target
For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.75 (Moderate Buy) |
ACER Stock Price Chart Interactive Chart >
ACER Price/Volume Stats
| Current price | $2.19 | 52-week high | $3.77 |
| Prev. close | $2.20 | 52-week low | $1.68 |
| Day low | $2.14 | Volume | 55,000 |
| Day high | $2.21 | Avg. volume | 312,909 |
| 50-day MA | $2.38 | Dividend yield | N/A |
| 200-day MA | $2.38 | Market Cap | 33.53M |
Acer Therapeutics Inc. (ACER) Company Bio
Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical OfficerIndustry veteran with over 20 years of drug development experience to oversee advancement of Acer’s product pipeline Adrian Quartel, MD, FFPM Dr. Quartel joins Acer Therapeutics as Chief Medical Officer NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the appo |
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised)Here is how Acer Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year. |
Acer Therapeutics to Participate in 2022 BIO CEO & Investor ConferenceNEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will virtually participate in the BIO CEO & Investor Conference on February 14-17, 2022. Format:On-demand recorded corporate presentation and one-on-one virtual meetingsDates:Februar |
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI ConferencesData to be presented suggests ACER-001 could represent a potential alternative to sodium and glycerol phenylbutyrate for treatment of UCDsNEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced the acceptance of four ACER-001 abstracts for poster presentations at the upcoming Society for Inherited Metabolic Disorders (SIMD) Annual M |
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year?Here is how Opexa Therapeutics, Inc. (ACER) and Aptinyx Inc. (APTX) have performed compared to their sector so far this year. |
ACER Price Returns
| 1-mo | 2.34% |
| 3-mo | -16.09% |
| 6-mo | -0.45% |
| 1-year | -22.34% |
| 3-year | -88.32% |
| 5-year | -67.94% |
| YTD | -3.95% |
| 2021 | -12.98% |
| 2020 | -34.66% |
| 2019 | -80.07% |
| 2018 | 45.27% |
| 2017 | 45.45% |
Loading social stream, please wait...